Description
Description
This page contains brief details about the drug abacavir,dolutegravir,lamivudine, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.
Date of Approval
Abacavir, Dolutegravir and Lamivudine is a combination regimen consisting of antiviral medications, which was approved for its medical use on 22nd August 2014.
Mechanism of Action of Abacavir,Dolutegravir,Lamivudine
Abacavir, Dolutegravir and Lamivudine Tablet is a combination of integrase strand transfer inhibitors and nucleoside analog reverse transcriptase inhibitors. It works by increasing the number of CD4 T cells and stimulates the immune system to fight against infections. Abacavir and Lamivudine inhibit the reverse transcriptase enzyme of the HIV-1, induce chain termination, and prevents the incorporation of viral DNA. Thereby, it reduces the viral load of HIV in the blood and decreases the severity of HIV infection.
Uses of Abacavir,Dolutegravir,Lamivudine
Abacavir, Dolutegravir, and Lamivudine have been developed to treat Human Immunodeficiency Virus (HIV-1). Abacavir, Dolutegravir, and Lamivudine Tablet is indicated as a complete regimen for treating adults and children infected with HIV 1.
Abacavir,Dolutegravir,Lamivudine Dosage available
Abacavir, Dolutegravir and Lamivudine is available as film-coated tablets and oral suspension. The tablets consist of 600mg of Abacavir, 50mg of Dolutegravir, and 300mg of Lamivudine. The usual recommended dosage of this combination regimen is one tablet every day with or without food.
